Chan Heng Fai Ambrose's Form 4 filing
Impact Biomedical Inc. (IBO) · filed Apr 7, 2025
- Accession no.
- 0001641172-25-003021
- Filed
- Apr 7, 2025
- Trade date
- Apr 3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $175.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chan Heng Fai AmbroseCIK 0001261725 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 | Common stock | SSaleDisposed | −351,555 | $0.50F1 | −$175,777.5 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On April 3, 2025, Alset International Limited sold 351,555 shares of the Issuer's common stock at a weighted average sale price of $0.495. This transaction was executed in multiple trades at prices ranging from $0.46 to $0.57. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.